# Phase 1 Study of F182112 in Patients With Relapsed or Refractory Multiple Myeloma

> **NCT04984434** · PHASE1 · UNKNOWN · sponsor: **Shandong New Time Pharmaceutical Co., LTD** · enrollment: 68 (estimated)

## Conditions studied

- Dose-Escalation Study, Relapsed or Refractory Multiple Myeloma

## Interventions

- **DRUG:** F182112

## Key facts

- **NCT ID:** NCT04984434
- **Lead sponsor:** Shandong New Time Pharmaceutical Co., LTD
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** UNKNOWN
- **Start date:** 2021-07-30
- **Primary completion:** 2023-07-30
- **Final completion:** 2023-12-30
- **Target enrollment:** 68 (ESTIMATED)
- **Last updated:** 2021-07-30


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT04984434

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT04984434, "Phase 1 Study of F182112 in Patients With Relapsed or Refractory Multiple Myeloma". Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/clinical/NCT04984434. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*